ReviewFrontiers in nutrition2026
Clinical evidence for microbial-derived polyphenol metabolites in health and disease: a scoping review.
Review in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Growing translational evidence indicates that the physiologically relevant effects of dietary (poly)phenols are largely mediated by gut microbial metabolism, resulting in bioactive microbial-derived (poly)phenol metabolites (MPMs). However, clinical evidence linking specific MPMs to defined health outcomes has not been comprehensively synthesized. Objective: This scoping review characterizes clinical studies assessing associations between MPMs and human health and disease. Methods: We systematically searched MEDLINE (PubMed), Embase (Elsevier), Web of Science (SCIE, ESCI), Scopus, ProQuest Health and Medical, the Cochrane Library, and ClinicalTrials.gov. Eligible studies quantified specific MPMs (e.g., urolithins, phenolic acids) in human biological specimens and assessed associations with biological or clinical outcomes. Two reviewers independently screened and extracted data using standardized forms. Findings were synthesized qualitatively. Results: Seventy studies across cardiometabolic, inflammatory/oxidative stress, neurological, gastrointestinal, cancer, musculoskeletal, epigenetic, and respiratory domains were included. Evidence was most concentrated in cardiometabolic outcomes ( Conclusion: Specific MPMs may contribute to inter-individual variability in diet-related health responses. Standardized metabolite assessment and prospective trials evaluating direct supplementation of specific microbial metabolites, particularly in individuals with limited systemic exposure, are needed to clarify their role in human health and inform precision nutrition strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.